Please assess the completion status of the following clinical trial:

Trial Title: Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of type 2 diabetes mellitus for at least six months~* 18 to 70 years of age, inclusive~* A1c ≥ 7.5% and ≤ 10%~* At least 3 months of continuous insulin and/or insulin analogue therapy (on at least 2 injections per day) +/- metformin prior to study entry~* Negative glutamic acid decarboxylase (GAD) autoantibodies~* Ability and willingness to perform self-monitoring of blood glucose (SMBG) at least four times a day, and at least 7 times daily during the 7-point blood glucose (BG) profile measurement days~* Ability and willingness to adhere to, and be compliant with, the study protocol~* Must be able to read English or Spanish at the sixth grade level in order to complete the patient-reported outcomes component of the study~* Signed informed consent~Exclusion Criteria:~* Subjects treated with sulfonylureas, thiazolidinediones (TZDs), or any other oral antidiabetic drugs (at study entry) except for insulin and/or insulin analogues with or without metformin~* Planned pregnancy; or pregnant or lactating females~* For subjects treated with metformin: serum creatinine ≥ 1.5 mg/dL (133 µmol/L) for males or ≥ 1.4 mg/dL (124 µmol/L) for females~* Serum creatinine ≥ 3.0 mg/dL (266 µmol/L)~* Any clinically significant renal disease (other than proteinuria) or hepatic disease~* Serum ALT or AST levels greater than 2.5 X the upper limit of normal~* Any current malignancy or any cancer within the past 5 years (except for adequately treated basal cell skin cancer or cervical carcinoma in situ)~* Diagnosis of dementia or mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study~* Diagnosis of impaired dexterity or vision rendering the subject unable to administer multiple daily injections (MDIs)~* Cardiac status New York Heart Association (NYHA) III-IV~* Hypersensitivity to Lantus or Apidra or any of their components~* Any disease or condition (including abuse of illicit drugs, prescription medicines or alcohol) that, in the opinion of the investigator or sponsor, may interfere with the completion of the study.~* Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study~* Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.
- 2 (Type: EXPERIMENTAL): POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).